Tesamorelin

Tesamorelin

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), comprising the full 44-amino acid sequence of endogenous GHRH with a trans-3-hexenoic acid modification at the N-terminus to enhance stability. It is a well-characterised GHRH receptor agonist that has been extensively studied in the context of growth hormone secretion, body composition, and metabolic regulation. Tesamorelin is supplied here as a lyophilised research compound for in vitro and preclinical investigation.

Mechanism of Action

Tesamorelin binds to and activates the GHRH receptor (GHRHR) on somatotroph cells of the anterior pituitary, stimulating the pulsatile release of endogenous growth hormone (GH). The resulting GH elevation promotes hepatic IGF-1 synthesis, which mediates downstream anabolic and lipolytic effects. Unlike exogenous GH administration, tesamorelin preserves the physiological pulsatility of GH secretion and operates within the feedback regulation of the somatotropic axis, making it a valuable tool for studying GHRH receptor pharmacology and GH-IGF-1 axis dynamics.

Research Applications

• GHRH receptor pharmacology and pituitary somatotroph function studies
• Growth hormone secretion and pulsatility modelling
• IGF-1 axis regulation and downstream signalling research
• Visceral adipose tissue metabolism and lipolysis investigation
• Body composition and metabolic syndrome preclinical models

Specifications

• Molecular Formula: C₂₂₁H₃₆₆N₇₂O₆₇S
• Molecular Weight: 5135.89 g/mol
• CAS Number: 218949-48-5
• Purity: ≥98%
• Form: Lyophilised powder
• Storage: -20°C
• Shelf Life: 24 months

This product is intended for legitimate laboratory and analytical research use only. Not for diagnostic, therapeutic, or consumer use.